Apixaban: an emerging oral factor Xa inhibitor
C Roser-Jones, RC Becker - 2010 - Springer
… Apixaban, an oral direct factor Xa inhibitor, is currently in late … (VTE) prophylaxis, apixaban
has shown decreased rates of … Secondary treatment of VTE with apixaban is currently in …
has shown decreased rates of … Secondary treatment of VTE with apixaban is currently in …
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - Taylor & Francis
… new oral anticoagulant agents have been developed that may offer an alternative to warfarin.
Emerging data suggest that Factor Xa … Direct Factor Xa inhibitors bind to Factor Xa with 1:1 …
Emerging data suggest that Factor Xa … Direct Factor Xa inhibitors bind to Factor Xa with 1:1 …
Apixaban: an oral direct factor-xa inhibitor
D Jiménez, RD Yusen, E Ramacciotti - Advances in therapy, 2012 - Springer
… new class of oral anticoagulants in patients with atrial fibrillation. In patients with acute coronary
syndrome, apixaban … course of thromboprophylaxis with apixaban was not superior to a …
syndrome, apixaban … course of thromboprophylaxis with apixaban was not superior to a …
The new factor Xa inhibitor: Apixaban
S Bhanwra, K Ahluwalia - Journal of Pharmacology and …, 2014 - journals.sagepub.com
… Efficacy profile of apixaban Apixaban is an oral selective direct factor Xa inhibitor, approved
by European commission, in May 2011 for the prevention of thromboembolic complications …
by European commission, in May 2011 for the prevention of thromboembolic complications …
[HTML][HTML] Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
PC Wong, DJP Pinto, D Zhang - Journal of thrombosis and thrombolysis, 2011 - Springer
… This review focuses on the pre-clinical discovery of apixaban, a promising new oral … of
the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor …
the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor …
Apixaban, an oral, direct factor X a inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
C Frost, J Wang, S Nepal, A Schuster… - British Journal of …, 2013 - Wiley Online Library
… , new oral agents targeted to inhibit thrombin or factor Xa have … Apixaban is a highly
selective, potent and orally bioavailable inhibitor of both free and prothrombinase-bound factor Xa. …
selective, potent and orally bioavailable inhibitor of both free and prothrombinase-bound factor Xa. …
Apixaban: a novel oral inhibitor of factor Xa
E Nutescu - American Journal of Health-System Pharmacy, 2012 - academic.oup.com
… Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a
… This review is timely since new results from Phase III trials of apixaban have recently been …
… This review is timely since new results from Phase III trials of apixaban have recently been …
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects
C Frost, S Nepal, J Wang, A Schuster… - British journal of …, 2013 - Wiley Online Library
… Apixaban is an oral factor Xa inhibitor … the new direct Xa inhibitors. In this study, mPT was
found to have greater sensitivity to apixaban and exhibited a linear relationship with apixaban …
found to have greater sensitivity to apixaban and exhibited a linear relationship with apixaban …
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of …
APPRAISE Steering Committee and Investigators - Circulation, 2009 - Am Heart Assoc
… in patients with recent acute coronary syndromes, which, depending on their results, may
establish oral anticoagulation as a new standard approach for preventing recurrent ischemic …
establish oral anticoagulation as a new standard approach for preventing recurrent ischemic …
[HTML][HTML] Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies
PC Wong, EJ Crain, B Xin, RR Wexler, PYS Lam… - Journal of Thrombosis …, 2008 - Elsevier
… , 0.05 ± 0.01, 0.05 ± 0.01, 0.27 ± 0.08 and > 3 mg kg −1 h −1 iv for the indirect FXa inhibitor …
1 po for the oral anticoagulant warfarin, respectively. Conclusions: In summary, apixaban was …
1 po for the oral anticoagulant warfarin, respectively. Conclusions: In summary, apixaban was …